PE20001089A1 - Metodo para incrementar la dureza y resistencia osea - Google Patents

Metodo para incrementar la dureza y resistencia osea

Info

Publication number
PE20001089A1
PE20001089A1 PE1999000839A PE00083999A PE20001089A1 PE 20001089 A1 PE20001089 A1 PE 20001089A1 PE 1999000839 A PE1999000839 A PE 1999000839A PE 00083999 A PE00083999 A PE 00083999A PE 20001089 A1 PE20001089 A1 PE 20001089A1
Authority
PE
Peru
Prior art keywords
pth
increases
parathyroid hormone
resistance
increase bone
Prior art date
Application number
PE1999000839A
Other languages
English (en)
Spanish (es)
Inventor
Janet M Hock
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26792729&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20001089(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PE20001089A1 publication Critical patent/PE20001089A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/29Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/18Drugs for disorders of the endocrine system of the parathyroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Materials For Medical Uses (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Steroid Compounds (AREA)
PE1999000839A 1998-08-19 1999-08-19 Metodo para incrementar la dureza y resistencia osea PE20001089A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9715198P 1998-08-19 1998-08-19
US9974698P 1998-09-10 1998-09-10

Publications (1)

Publication Number Publication Date
PE20001089A1 true PE20001089A1 (es) 2000-11-04

Family

ID=26792729

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1999000839A PE20001089A1 (es) 1998-08-19 1999-08-19 Metodo para incrementar la dureza y resistencia osea

Country Status (32)

Country Link
US (2) US6977077B1 (OSRAM)
EP (3) EP1059933B1 (OSRAM)
JP (5) JP2002523375A (OSRAM)
KR (1) KR100454207B1 (OSRAM)
CN (1) CN1205997C (OSRAM)
AR (1) AR033639A1 (OSRAM)
AT (1) ATE231000T1 (OSRAM)
AU (1) AU746277B2 (OSRAM)
BR (1) BR9909445A (OSRAM)
CA (1) CA2325371C (OSRAM)
CO (1) CO5130020A1 (OSRAM)
CY (2) CY1113343T1 (OSRAM)
CZ (1) CZ301017B6 (OSRAM)
DE (2) DE15152726T1 (OSRAM)
DK (4) DK1769804T3 (OSRAM)
DZ (1) DZ2873A1 (OSRAM)
EA (1) EA003362B1 (OSRAM)
ES (4) ES2393200T3 (OSRAM)
HR (1) HRP20000755A2 (OSRAM)
HU (2) HU1200430D0 (OSRAM)
ID (1) ID29039A (OSRAM)
IL (2) IL138829A0 (OSRAM)
MY (1) MY129227A (OSRAM)
NO (2) NO323984B1 (OSRAM)
NZ (1) NZ507056A (OSRAM)
PE (1) PE20001089A1 (OSRAM)
PL (1) PL201688B1 (OSRAM)
PT (4) PT2266598T (OSRAM)
TR (1) TR200003455T2 (OSRAM)
TW (1) TW576747B (OSRAM)
UA (1) UA72205C2 (OSRAM)
WO (1) WO2000010596A1 (OSRAM)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6770623B1 (en) * 1997-12-09 2004-08-03 Eli Lilly And Company Stabilized teriparatide solutions
US20040033950A1 (en) * 2000-09-26 2004-02-19 Hock Janet M. Method of increasing bone toughness and stiffness and reducing fractures
DZ2873A1 (fr) * 1998-08-19 2003-12-15 Lilly Co Eli Procédé pour augmenter la dureté et la rigidité osseuse.
CA2387693A1 (en) * 1999-09-20 2001-03-29 Eli Lilly And Company Method for monitoring treatment with a parathyroid hormone
US7247609B2 (en) 2001-12-18 2007-07-24 Universitat Zurich Growth factor modified protein matrices for tissue engineering
EP1531855A4 (en) * 2002-01-10 2009-07-22 Osteotrophin Llc TREATMENT OF BONE DISEASES WITH SKELETTAL ANABOLIKA
US8088734B2 (en) 2003-01-21 2012-01-03 Unigene Laboratories Inc. Oral delivery of peptides
RU2006108557A (ru) * 2003-09-19 2007-09-27 Пфайзер Продактс Инк. (Us) Фармацевтические композиции, включающие в себя сочетания производных 2-алкилиден-19-нор-витамина d и паратиреоидного гормона, и способы (лечения)
US20060127320A1 (en) * 2004-05-10 2006-06-15 Nastech Pharmaceutical Company Inc. Method of delivering parathyroid hormone to a human
CA2567056A1 (en) * 2004-05-10 2005-12-08 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of parathyroid hormone
US20060189533A1 (en) * 2004-05-10 2006-08-24 Nastech Pharmaceutical Company Inc. Stable pharmaceutical dosage forms of teriparatide
US20060052305A1 (en) * 2004-05-10 2006-03-09 Nastech Pharmaceutical Company Inc. Method of treating osteoporosis using intranasal parathyroid hormone
EP1744683B1 (en) 2004-05-13 2016-03-16 Alza Corporation Apparatus and method for transdermal delivery of parathyroid hormone agents
US7648965B2 (en) 2004-05-14 2010-01-19 Unigene Laboratories Inc. Method for fostering bone formation and preservation
WO2006124062A1 (en) * 2005-05-11 2006-11-23 Unigene Laboratories, Inc. Method for fostering bone formation and preservation
US20060069021A1 (en) * 2004-08-13 2006-03-30 Nastech Pharmaceutical Company Inc. Compositions and methods for intranasal administration of inactive analogs of PTH or inactivated preparations of PTH or PTH analogs
WO2006073711A2 (en) * 2005-01-06 2006-07-13 Kuros Biosurgery Ag Use of a matrix comprising a contrast agent in soft tissues
US8575101B2 (en) 2005-01-06 2013-11-05 Kuros Biosurgery Ag Supplemented matrices for the repair of bone fractures
US20070173447A1 (en) * 2005-10-25 2007-07-26 Nastech Pharmaceutical Company Inc. Method for treating osteoporosis by intranasal delivery of teriparatide with an anti-resorptive agent
CN101355959B (zh) * 2005-11-10 2013-02-27 密歇根理工大学管理委员会 黑熊甲状旁腺素和使用黑熊甲状旁腺素的方法
US20080051332A1 (en) * 2005-11-18 2008-02-28 Nastech Pharmaceutical Company Inc. Method of modulating hematopoietic stem cells and treating hematologic diseases using intranasal parathyroid hormone
US20080119408A1 (en) * 2006-07-07 2008-05-22 Nastech Pharmaceutical Company Inc. Pth formulations for intranasal delivery
EP1961765A1 (en) * 2006-12-08 2008-08-27 Zealand Pharma A/S Truncated PTH peptides with a cyclic conformation
ES2381639T3 (es) 2007-04-13 2012-05-30 Kuros Biosurgery Ag Sellante polimérico para tejidos
US20110137243A1 (en) * 2007-09-06 2011-06-09 Abbott Cardiovascular Systems Inc. Coating On A Balloon Device
EP2217260B1 (en) * 2007-12-04 2016-11-09 Ben-Gurion University Of The Negev Research And Development Authority Amphiphilic peptide matrices for treatment of osteoporosis
WO2009083544A2 (en) 2007-12-28 2009-07-09 Kuros Biosurgery Ag Pdgf fusion proteins incorporated into fibrin foams
ES2843649T3 (es) 2009-09-09 2021-07-20 Asahi Kasei Pharma Corp Agente terapéutico/profiláctico que contiene PTH para la osteoporosis, caracterizado porque la PTH se administra una vez por semana en una dosis unitaria de 200 unidades
EP2509996A1 (en) 2009-12-07 2012-10-17 Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
US9295663B2 (en) 2010-07-14 2016-03-29 Abbott Cardiovascular Systems Inc. Drug coated balloon with in-situ formed drug containing microspheres
WO2012111852A1 (ja) * 2011-02-17 2012-08-23 帝人ファーマ株式会社 椎体骨折治療剤及びその評価方法
EP2686027B1 (en) 2011-03-16 2021-05-05 Kuros Biosurgery AG Pharmaceutical formulation for use in spinal fusion
ES2761635T3 (es) 2011-06-07 2020-05-20 Asahi Kasei Pharma Corp Preparación liofilizada que contiene PTH de alta pureza y método para producirla
US9700485B2 (en) 2013-04-24 2017-07-11 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
EP3411066A1 (en) 2016-02-01 2018-12-12 Eli Lilly and Company Parathyroid hormone anti-rankl antibody fusion compounds
JP2020506926A (ja) * 2017-02-01 2020-03-05 ザ・ジョンズ・ホプキンス・ユニバーシティ 副甲状腺ホルモンと変性椎間板疾患の再生
JP6577683B2 (ja) * 2017-09-22 2019-09-18 旭化成ファーマ株式会社 安定性に優れるテリパラチド含有液状医薬組成物
WO2020090174A1 (ja) 2018-10-29 2020-05-07 旭化成ファーマ株式会社 週2回の頻度でテリパラチド又はその塩を投与することを特徴とする、骨粗鬆症の予防又は治療方法
JP7684951B2 (ja) 2019-08-09 2025-05-28 フラッグシップ・パイオニアリング・イノベーションズ・ブイアイ,エルエルシー 副甲状腺ホルモン受容体(pthr1)の調節剤
GB2590692A (en) * 2019-12-24 2021-07-07 Corthotec Ltd Composition for improved bone fracture healing

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4086196A (en) 1975-03-28 1978-04-25 Armour Pharmaceutical Company Parathyroid hormone
IL78342A (en) * 1985-04-04 1991-06-10 Gen Hospital Corp Pharmaceutical composition for treatment of osteoporosis in humans comprising a parathyroid hormone or a fragment thereof
DE3935738A1 (de) 1989-10-27 1991-05-08 Forssmann Wolf Georg Arzneimittel, enthaltend das humane parathormon-fragment (1-37) als aktiven wirkstoff
US5208041A (en) 1991-05-23 1993-05-04 Allelix Biopharmaceuticals Inc. Essentially pure human parathyroid hormone
US5556940A (en) 1994-06-20 1996-09-17 National Research Council Of Canada Parathyroid hormone analogues for the treatment of osteoporosis
JPH0873376A (ja) * 1994-09-07 1996-03-19 Asahi Chem Ind Co Ltd 骨粗鬆症治療薬
US5747456A (en) * 1994-12-19 1998-05-05 Beth Israel Deaconess Medical Center Continuous low-dose administration of parathyroid hormone or its agonist
WO1996019246A1 (en) * 1994-12-19 1996-06-27 Beth Israel Hospital Association Continuous low-dose administration of parathyroid hormone or its agonist
HU218940B (hu) * 1994-12-22 2001-01-29 Astra Aktiebolag Paratiroid hormont (PHT) tartalmazó, inhalációs célra szolgáló gyógyszerkészítmény, eljárás előállítására, alkalmazása inhalációs készülék töltésére és ezt tartalmazó inhalációs készülék
JPH08310965A (ja) * 1995-05-16 1996-11-26 Chugai Pharmaceut Co Ltd 骨癒合促進剤
CA2302255C (en) * 1997-09-09 2011-11-08 F. Hoffmann-La Roche Ag Fracture healing using pthrp analogs
MY120063A (en) 1997-12-09 2005-08-30 Lilly Co Eli Stabilized teriparatide solutions
US20040033950A1 (en) 2000-09-26 2004-02-19 Hock Janet M. Method of increasing bone toughness and stiffness and reducing fractures
DZ2873A1 (fr) 1998-08-19 2003-12-15 Lilly Co Eli Procédé pour augmenter la dureté et la rigidité osseuse.
US6907597B1 (en) 2000-10-13 2005-06-14 Ati International Srl Method and apparatus for constructing an executable program in memory
US6967759B2 (en) 2001-12-31 2005-11-22 Texas Instruments Incorporated Pulse width modulation sequence generation
JP5796714B2 (ja) 2012-01-13 2015-10-21 株式会社リコー 定着装置及び画像形成装置
EP2949301B1 (en) 2014-05-27 2018-04-18 The Procter and Gamble Company Absorbent core with curved and straight absorbent material areas

Also Published As

Publication number Publication date
EP2907522A1 (en) 2015-08-19
HUP0101594A3 (en) 2002-01-28
WO2000010596A1 (en) 2000-03-02
HK1212602A1 (en) 2016-06-17
DK1769804T3 (da) 2012-10-15
NO20005947D0 (no) 2000-11-24
US7163684B2 (en) 2007-01-16
CA2325371A1 (en) 2000-03-02
PT2266598T (pt) 2017-05-02
ES2393200T3 (es) 2012-12-19
PT1059933E (pt) 2003-06-30
PT1769804E (pt) 2012-11-13
PL201688B1 (pl) 2009-04-30
EA200001015A1 (ru) 2001-02-26
CN1308545A (zh) 2001-08-15
ID29039A (id) 2001-07-26
DZ2873A1 (fr) 2003-12-15
CO5130020A1 (es) 2002-02-27
CZ301017B6 (cs) 2009-10-14
HU1200430D0 (hu) 2001-11-28
EP2907522B1 (en) 2017-08-02
ES2190244T3 (es) 2003-07-16
DE69904918T2 (de) 2003-11-13
HU230697B1 (hu) 2017-09-28
KR20010072763A (ko) 2001-07-31
US6977077B1 (en) 2005-12-20
DK2907522T3 (en) 2017-10-23
DE15152726T1 (de) 2015-12-10
DK1059933T3 (da) 2003-04-07
NO20005947L (no) 2000-11-24
UA72205C2 (uk) 2005-02-15
NO20072983L (no) 2000-11-24
CY1113343T1 (el) 2016-06-22
DE69904918D1 (de) 2003-02-20
DK2266598T3 (en) 2017-05-15
PL343595A1 (en) 2001-08-27
NO323984B1 (no) 2007-07-30
EP1059933A1 (en) 2000-12-20
ES2549551T1 (es) 2015-10-29
EP2266598B1 (en) 2017-02-22
CA2325371C (en) 2004-08-17
AU5575099A (en) 2000-03-14
ES2621653T3 (es) 2017-07-04
JP2015028065A (ja) 2015-02-12
HRP20000755A2 (en) 2001-02-28
CN1205997C (zh) 2005-06-15
EA003362B1 (ru) 2003-04-24
JP2014139220A (ja) 2014-07-31
TW576747B (en) 2004-02-21
US20050197294A1 (en) 2005-09-08
EP2266598A1 (en) 2010-12-29
CY1119552T1 (el) 2018-03-07
CZ20004134A3 (cs) 2001-08-15
JP2011021035A (ja) 2011-02-03
NZ507056A (en) 2003-10-31
IL138829A0 (en) 2001-10-31
HUP0101594A2 (hu) 2001-11-28
JP6177718B2 (ja) 2017-08-09
JP2017190332A (ja) 2017-10-19
TR200003455T2 (tr) 2001-06-21
ES2549551T3 (es) 2017-11-27
KR100454207B1 (ko) 2004-10-26
AR033639A1 (es) 2004-01-07
BR9909445A (pt) 2000-12-12
HK1030545A1 (en) 2001-05-11
ATE231000T1 (de) 2003-02-15
PT2907522T (pt) 2017-10-23
EP1059933B1 (en) 2003-01-15
IL138829A (en) 2011-01-31
AU746277B2 (en) 2002-04-18
JP2002523375A (ja) 2002-07-30
DK2907522T1 (da) 2015-10-19
HK1102496A1 (en) 2007-11-23
MY129227A (en) 2007-03-30

Similar Documents

Publication Publication Date Title
PE20001089A1 (es) Metodo para incrementar la dureza y resistencia osea
US10022165B2 (en) Orthopedic fastener device
de Vries et al. Treatment of subtrochanteric nonunions
WO2002034148A3 (en) Systems and methods for reducing fractured bone using a fracture reduction cannula
Hirvensalo et al. Fracture of the humeral capitellum fixed with absorbable polyglycolide pins: 1-year follow-up of 8 adults
ATE318559T1 (de) Vorrichtungen zur behandlung von gebrochenen und/oder erkrankten knochen
Gadegone et al. Long proximal femoral nail in ipsilateral fractures proximal femur and shaft of femur
Gadegone et al. Short proximal femoral nail fixation for trochanteric fractures
CA2343378A1 (en) Fracture fixation system
DE59711081D1 (de) Marknagelsystem zur frakturheilung bzw. knochenverlängerung
ZICKEL et al. Zickel supracondylar nails for fractures of the distal end of the femur
Frölke et al. ĮDESTINATION OF DEBRIS DURING INTRAMEDULLARY REAMING AN EXPERIMENTAL, STUDY (ON SHEEP PEMURS
WO2015137911A1 (en) Orthopedic fastener device
Wroblewski et al. Wear of enhanced ultra-high molecular-weight polyethylene (Hylamer) in combination with a 22.225 mm diameter zirconia femoral head
Patil et al. Role of Cemented Bipolar Hemiarthroplasty for Comminuted Inter-trochanteric Femur Fracture in elderly osteoporotic patients through a modified Transtrochanteric approach—“SION Hospital Modification”
Leung Reconstruction of a large femoral defect using a vascular pedicle iliac graft. Case report.
Bisbinas et al. Reamer breakage in the femoral medulla during total knee arthroplasty: should reamers have a finite life?
RU2837475C1 (ru) Способ лечения пациента с несостоятельным дистракционным костным регенератом в стадии оссификации
WO2016063193A1 (en) Intertrochanteric fixation device
Kurdy et al. The Huckstep Nail: Stable Fixation of Mechanically Deficient Femoral Bone.
Cantlon et al. Calcium phosphate cement augmentation of proximal humerus fractures
Phemister Aseptic Necrosis of Bone Management and Prognosis
Shrestha et al. Intramedullary pinning for surgical correction of condylar fracture in a dog
Goh et al. Augmentation of Osteoarticular Allograft Reconstruction With Photodynamic Nail for the Management of Primary or Recurrent Aggressive Giant Cell Tumor in the Distal Radius
Misra Implantology of Fractures of the Shaft of Femur Including Segmental and Combination Fractures

Legal Events

Date Code Title Description
FC Refusal